Use of polydatine for treating hepatic diseases and polydatine pharmaceutical composition. RU patent 2468803.

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are presented the use of polydatine for treating toxic (including drug-induced) and alcoholic hepatic diseases, as well as based oral compositions. What is shown is reduction of a degree of hepatocyte adipose degeneration in sub-acute alcoholisation, reduction of glycemia and lactate-acidosis. Polydactine promoted reduction of synthesis and accumulation of glycosaminoglycans.

EFFECT: invention may be used for treating toxic hepatitis, including of drug-induced and alcoholic nature; hepatic adipose degeneration (hepatic steatosis), including of nonalcoholic fatty liver disease (steatohepatitis); hepatic cirrhosis.

4 cl, 1 dwg, 2 tbl

IPC classes for russian patent Use of polydatine for treating hepatic diseases and polydatine pharmaceutical composition. RU patent 2468803. (RU 2468803):

A61P1/16 - for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

A61K31/7034 -

Another patents in same IPC classes:

Method of preventing chronic toxic hepatopathy / 2468446
In order to prevent chronic toxic hepatopathy melaxen is introduced to animals in experiment one time per day in dose 10 mg/ml through probe into stomach. Simultaneously intragastric introduction of cobalt chloride solution in dose 2 mg/kg, in terms of metal, is performed daily, to create cobalt intoxication in organism.

Method for preparing agent showing cholagogue action / 2465000
Invention refers to pharmaceutical industry, specifically to an agent showing cholagogue action. A method for preparing the agent showing cholagogue action consisting in the fact that ground sandy everlasting blossom, nosebleed herb and peppermint leaves are mixed with coriander fruit, extracted in 40% ethanol by multistage counterflow extraction, settled, filtered, condensed under certain conditions.

Quinazoline derivative and pharmaceutical preparation / 2464263
Invention relates to a quinazoline derivative of general formula [1], or a pharmaceutically acceptable salt thereof [1], where R1-R6 assume values given claim 1, except compounds in which R5 is hydrogen and R6 is -NH2. The invention also relates to a pharmaceutical composition having the activity of an antipruritic agent, containing as an active ingredient said quinazoline derivative or pharmaceutically acceptable salt thereof.

Agent of saussurea ds plants possessing hepatoprotective action / 2464036
Invention refers to pharmaceutical industry, particularly to an agent possessing hepatoprotective activity and an ability to normalise the hepatic function. The use of a ground elevated part of Saussurea plants or an aqueous or aqueous-alcoholic or supercritical fluid extract of the elevated part of Saussurea plants as the agent possessing hepatoprotective activity and the ability to normalise the hepatic function.

Use of modified cyclosporines / 2463071
Group of inventions refers to medicine, particularly the use of non-immunosuppressive cyclophilin-binding cyclosporine for preventing or treating transplantation-related cirrhosis wherein cyclosporine (I) binds to human recombinant cyclophilin with a binding constant (BR) making less than 0.7 wherein BR represents a common logarithm of IC50 cyclosporine to IC50 cyclosporine A relation in concurrent experiment when evaluating by ELISA procedure; and (II) has activity in lymphocyte assay in the mixed culture making no more than 5% as compared with cyclosporine A activity (cl. 1) of the patent claim. There are also disclosed a pharmaceutical composition and a pharmaceutical combination containing cyclosporine under cl. 1.

Phospholipid nanoform for oral application (sachet) and method for preparing it (versions) / 2463057
Invention refers to medicine, pharmacology and concerns an oral granulated dosage form in sachets containing phospholipids in the form of particles of small (20-30 nm) diameter, glycyrrhizic acid and its salt (including sodium glycerrhizinate), as well as carbohydrate (including maltose) and excipients (granulation, anti-clotting and powder), as well as to a method for preparing it by mixing fat and water phases of herbal phospholipids and acceptable carbohydrate to prepare an emulsion, cooling to 50°C and passing through a microfluidiser for 4-5 cycles under pressure 2000 atm.

Agent showing hepatoprotective action, and method for preparing it / 2462259
Invention refers to pharmaceutical industry, specifically to an agent showing hepatoprotective action. The agent showing hepatoprotective action of a herbal polyphenol extract of Amur maackia heartwood (Maxar) which represents an aqueous solution of Maxar in the molecular-capsulated form in the form of a water-soluble associated with a surfactant having a specific hydrophilic-lipophilic balance. A method for preparing the agent showing hepatoprotective action by Maxar homogenisation in the melt surfactant under certain conditions to produce the molecular-capsulated form of the end product.

Method of treating patients with chronic liver diseases in stage of latency and degree i manifested stage of hepatic encephalopathy / 2462251
Invention refers to medicine and aims at treating the patients with chronic liver diseases (CLD) in the stage of latency and degree I manifested stage of hepatic encephalopathy. The preparation Essentiale forte N is used. It is combined with prescribing the preparation Mucofalk. The course is 28-30 days.

Method of treating chronic viral hepatitis c / 2459629
Invention refers to medicine, namely hepatology and may be applicable in treating chronic viral hepatitis C. That is ensured by introducing short-lived interferon-alpha (IFN) and the nucleoside analogue Ribamidil in the patient with an initial average week dosage specified in the range of 10.5 to 21.0 mil. IU depending on the level of native patient's interferon-alpha. Interferon-alpha is introduced with at least twice gradually increase of the average week dose to 21.0 to 84 mil. IU. Over the whole period of introducing IFN, the patient is prescribed with additional antiviral preparations - an interferon inducer, as well as an amantadin preparation or a glycyrrhizic acid preparation. It is combined with a support therapy involving the introduction of T-cell immunity stimulators and preparations for correction of side effects. The presence of blood viral ribonucleic acid is occasionally controlled and the introduction of Ribamidil is started in a daily dose of 800-1200 mg from the third month from the beginning of treatment if observing the presence of ribonucleic acid or from the tenth month if observing the absence. The treatment is continued until at least a 12-month aviremia period is achieved.

Method of prevention and treatment of liver disease with application of receptor a<sub>2b</sub> antagonists

Method of prevention and treatment of liver disease with application of receptor a_2b antagonists / 2457842
Group of inventions relates to field of medicine. Method of treatment and prevention of liver fibrosis includes peroral introduction to mammal of therapeutically efficient amount of antagonist of adenosine receptor A2B - 3-ethyl-1-propyl-8-(1-{[3-(trifluormethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione. Method of reducing hepatotoxic side effects of chemical therapy or radiotherapy includes peroral introduction to mammal who underwent such treatment of therapeutically efficient amount of antagonist of adenosine receptor A2B - 3-ethyl-1-propyl-8-(1-{[3-(trifluormethyl)phenyl]methyl}pyrazol-4-yl) -1,3,7-trihydropurine-2,6-dione.

New aminoglycoside antibiotics / 2458931
What is disclosed is a new aminoglycoside antibiotic which possesses excellent antibacterial activity against a bacterium inducing an infection, particularly MRSA, and also possesses low renal toxicity. A method for making said antibiotic is described. More specifically, there are disclosed a compound presented by formula (Ia) wherein the radical values are specified in the description, or its pharmaceutically acceptable salt or solvate, or mixed diastereomers of the compound; an antibacterial agent containing the compound, pharmacologically acceptable salt, solvate or mixed diastereomers; and a method for producing said compound.

Oligosaccharide substrates, modified with fluorescent group, for detecting cellulase complex enzymes on solid media / 2378283
Invention relates to oligosaccharide substrates modified with a fluorescent group (see general structural formula given below ) which are soluble in water, for detecting cellulase complex enzymes on solid (agarised) media, where n (degree of polymerisation) equals 2-4, and the fluorescent group used is 2-(2'-hydroxyphenyl)-benzothiazole.

Substrates of oligasaccharide class for detecting endo-glycosidehydrolase in presence of exo-acting ferments / 2378282
Invention refers to substrates of oligosaccharide class for detecting endo-glycosidehydrolase in presence of exo-acting ferments of general formula specified below, where X - oxygen atom or sulphur atom, and finite non-reducing sugar residual matter is connected to glyconic part of substrate molecule with thio-connection, at that n ≥ 0.

Novel aromatic fluoroglycoside derivatives, medications, containing said compounds and their application / 2340622
In substituted aromatic derivatives of formula (Ib) R1 and R2 independently represent H or F, one of R1 or R2 residues must represent F; R3 - OH; A represents O; R4 - hydrogen, (C1-C6)-alkyl, (C1-C6)-alkoxy or OH; R5 -hydrogen, (C1-C6)-alkoxy or halogen; R6 - hydrogen, halogen or OH; B - (C1-C6)-alkandiyl, -CO-NH-CH2-, -O- or -CO-CH2-CH2-; R7 - hydrogen; R8 - hydrogen, OH, (C1-C6)-alkyl, halogen or (C1-C6)-alkoxy, which is optionally single- or multi- substituted with fluorine; R9 - hydrogen; or R8 and R9 together represent -CH=CH-O- or -CH2-CH2-O-,forming together with carbon atoms to which they are bound, Cyc2 -furanyl or dihydrofuranyl, respectively; as well as to their pharmaceutically acceptable salts.

Derivatives of aryl-5-thio-β-d-glycopyranoside and therapeutic agent comprising thereof used in diabetes mellitus / 2322449
Invention relates to a derivative of 5-thio-β-D-glucopyranoside of the formula (i): wherein Y represents -O- or -NH-; R2, R2 or R3 represents hydrogen atom, acyl or phenyl-(C1-C4)-alkyl; R4 represents hydrogen atom, acyl, alkoxycarbonyl or phenyl-(C1-C4)-alkyl; Ar represents phenyl or naphthyl substituted with -X-A1, and phenyl can be substituted additionally with 1-3 similar or different substitutes chosen from halogen atom, hydroxyl and others; X represents -(CH2)n-, -CO(CH2)n-, -CH(OH)(CH2)n-, -O-(CH2)n-, -CONH(CH2)n- wherein n means a whole number from 0 to 3, -COCH=CH-, -S- or -NH-; A1 represents phenyl, naphthyl or heteroaryl chosen from benzofuranyl group, pyridyl group, pyrazolyl group and thiazolyl group wherein three latter groups can be substituted additionally with alkyl, and phenyl group can be substituted with 1-4 similar or different substitutes chosen from halogen atom, hydroxyl and others; or its pharmaceutically acceptable salt or its hydrate. Derivatives of the formula (i) possess inhibitory effect with respect to SGLT2 activity. Also, invention relates to a pharmaceutical composition representing prophylactic or therapeutic agent used in diabetes mellitus, diseases or complications associated with diabetes mellitus. Also, invention relates to a derivative of 5-thio-β-D-glucopyranoside of the formula (III): wherein R21, R22, R23 and R24 means hydrogen atom or acyl; R25 means amino group, alkanoyl, carboxyl or alkoxycarbonyl; R26 means hydrogen atom or hydroxy group; R27 means hydrogen atom or alkyl; or to its pharmaceutically acceptable salt or hydrate. Derivatives of the formula (III) are intermediate compound used in synthesis of compounds of the formula (I): wherein Y means -O-; each among R1, R2 or R3 represents hydrogen atom, acyl or phenyl-(C1-C4)-alkyl; R4 represents hydrogen atom, acyl, alkoxycarbonyl or phenyl-(C1-C4)-alkyl; one radical among R5, R6, R7, R8 and R9 represents -X-A1 (wherein X and A1 have values given above), and others represent hydrogen atom, halogen atom and others.

O-arylglucoside inhibitors of sglt2 and method for their using / 2269540
Invention relates to O-arylglucoside inhibitors of SGLT2 of the formula (I): wherein Y means compounds of formulae: A means -O(CH2)m, sulfur atom (S), -NH(CH2)m or -(CH2)n wherein n = 0-3; m = 0-2; R1-R6 are determined above, and to a pharmaceutical composition based on thereof, and to methods for treatment of diabetes mellitus type 2, and micro- and macrovascular diabetic complications.

Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions comprising these derivatives and intermediate compounds for preparing indicated derivatives / 2254340
Invention relates to new derivatives of glucopyranosyloxybenzylbenzene represented by the formula (I): wherein R1 represents hydrogen atom or hydroxy(lower)alkyl; R2 represents lower alkyl group, lower alkoxy-group and lower alkylthio-group being each group is substituted optionally with hydroxy- or (lower)alkoxy-group, or to its pharmaceutically acceptable salts. Also, invention relates to pharmaceutical composition eliciting hypoglycemic activity and to a method for treatment and prophylaxis of hyperglycemia-associated diseases, such as diabetes mellitus, obesity and others, and to their intermediate compounds. Invention provides preparing new derivatives of glucopyranosyloxybenzylbenzene that elicit the excellent inhibitory activity with respect to human SGLT2.